HARP News and Press, Harpoon Therapeutics Inc. From 09/09/20

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate ...

Guess' (NYSE: GES ) +25%  on Q2 results . More news on: Guess', Inc., TSR, Inc., Vera Bradley, Inc., Stocks on the move, , Read more ...

Aimmune Therapeutics (NASDAQ: AIMT ) +171%  on being acquired by Nestle. More news on: Aimmune Therapeutics, Inc., Akcea Therapeutics, Inc., Genworth Financial, Inc., , , Read more ...

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Karin Ann Thacker, M.Sc., as Vice President, Regulatory Affairs an...

Sonnet BioTherapeutics Holdings (NASDAQ: SONN ) +67%  on FDA nod for convalescent plasma. More news on: Sonnet BioTherapeutics Holdings, Inc., Liminal BioSciences Inc., ADMA Biologics, Inc., Stocks on the move, , Read more ...

Gainers:  Hancock Jaffe Laboratories (NASDAQ: HJLI ) +127% . More news on: Hancock Jaffe Laboratories, Inc., Harpoon Therapeutics, Inc., ShiftPixy, Inc., Stocks on the move, , Read more ...

Harpoon Therapeutics (NASDAQ: HARP ) : Q2 GAAP EPS of -$0.51 misses by $0.01 . More news on: Harpoon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Presented positive interim Phase 1 clinical trial data for PSMA-targeting HPN424 in prostate cancer at ASCO20, supporting increased dose escalation Dosed first patient with HPN217 targeting BCMA for the treatment of multiple myeloma, triggering a $50 million milestone payment from A...

Joanne Viney, Ph.D., brings expertise as an immunologist and veteran biotech executive to the board Drs. Luke Evnin and Patrick Baeuerle step down from the Harpoon board Dr. Baeuerle remains as a scientific advisor to the company SOUTH SAN FRANCISCO, Calif., July 02, 2020 (GLO...

SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced new information regarding its participation in two upcoming investor virtual conferen...